02509 荃信生物－Ｂ
按盘价 
10.900 -0.140 (-1.268%) 盈利能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | -37.716% | -55.471% | -28.364% | -27.941% |
| 股东资金回报率 (%) | -128.145% | -108.438% | -45.454% | -44.495% |
| 资本运用回报率 (%) | -60.604% | -93.369% | -32.664% | -29.892% |
边际利润分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 58.059% | N/A | N/A | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -189.858% | N/A | N/A | N/A |
| 税前边际利润率 (%) | -220.262% | N/A | N/A | N/A |
| 纯利率 (%) | -211.328% | N/A | N/A | N/A |
变现能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 1.434 X | 1.662 X | 5.205 X | 9.304 X |
| 速动比率 (X) | 1.426 X | 1.647 X | 5.205 X | 9.304 X |
财务杠杆分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 77.533% | 62.172% | 36.102% | 34.036% |
| 总债项 / 总资产比率 (%) | 53.624% | 43.498% | 28.524% | 27.191% |
| 净债项 / 总资产比率 (%) | 16.964% | 16.310% | 7.938% | 6.764% |
| 总债项 / 股东资金比率 (%) | 230.414% | 117.402% | 46.010% | 43.300% |
| 长期债项 / 股东资金比率 (%) | 137.827% | 76.355% | 36.308% | 40.939% |
| 净债项 / 股东资金比率 (%) | 72.892% | 44.021% | 12.804% | 10.771% |
| 净现金 / (债项) ($) | (1.67亿) | (1.30亿) | (8.22千万) | (7.22千万) |
| 每股净现金 / (债项) ($) | (0.752) | -- | -- | -- |
| 总债项 / 资本运用比率 (%) | 95.283% | 63.636% | 32.342% | 29.090% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A |
营运效率分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | 19.483日 | -- | N/A | N/A |
| 应收贸易帐周转率日数 (日) | 60.409日 | N/A | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 211.290日 | N/A | N/A | N/A |
| 备注： | 实时报价更新时间为16/05/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -335,574,000 |
| 增长率 | -33.909% |
| 每股盈利/(亏损) | RMB -1.530 |
| 每股账面资产净值 (¥) | RMB 1.031 |